Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –
– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –